Biotech / Finance

Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer's Disease

From Biotech
March 20, 2017 - 7:07am
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer's disease, announced that they received a Phase 2 SBIR grant award by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The grant award for $1.8 million will fund research and development of a novel ophthalmic diagnostic probe for Alzheimer's Disease. The company previously was awarded a Phase 1 grant from 2015-2016.  Alzheimer's disease is a significant healthcare burden and unmet medical need. Buildup and deposition of amyloid-beta plaques in the brain is a hallmark of the disease, and this accumulation continues to be the leading biomarker of interest for early detection. Accrual of amyloid-beta is believed to typically occur well before the appearance of clinical symptoms of cognitive decline. The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer's disease ...Full story available on

Continue reading this article »